GlaxoSmithKline
NEWS
The company is expanding its manufacturing efforts in Europe, Canada, the United Kingdom and the United States in order to meet this goal.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 28, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 14, 2020.
Zejula, GlaxoSmithKline’s once-daily PARP inhibitor, won regulatory approval as a monotherapy maintenance treatment for women with advanced ovarian cancer whose disease is responsive to first-line platinum-based chemotherapy, regardless of biomarker status.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
BioSpace takes an in-depth look at the human immunodeficiency virus including research, drugs in the pipeline and treatments. Check out the free downloadable report.
The discovery that immune T cells have a spectrum of responsiveness could shed light on how our immune system responds to infections and cancer, and what goes wrong in immune diseases.
It’s likely that more companies and universities will add additional assets as time goes on.
JOBS
IN THE PRESS